Structural Racism & Science: Health Evidence vs. Ideology
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals wiht...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard...
- The increased risk appears to be concentrated in individuals already diagnosed with established cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals wiht obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Tho, it’s crucial to note that the trial also showed a significant reduction in the advancement of type 2 diabetes among participants.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| New-Onset Type 2 Diabetes | 15.0 | 25.3 | 0.61 |
Who is Affected? Understanding the Patient Profile
The increased risk appears to be concentrated in individuals already diagnosed with established cardiovascular disease. This includes those with a history of heart attack, stroke, or peripheral artery disease. The trial did not include patients with heart failure, so the findings cannot be extrapolated to this population. Individuals without pre-existing heart conditions did not show the same increased risk in this study.
it’s crucial to emphasize that this doesn’t mean semaglutide is inherently dangerous for everyone. Rather, it highlights the need for a more nuanced approach to prescribing these medications, notably in vulnerable populations.
Why Does This Matter? The Implications for Obesity Treatment
Semaglutide, marketed as Ozempic and Wegovy, has become a widely prescribed medication for weight loss, often touted as a breakthrough in obesity treatment. These findings challenge that narrative and underscore the importance of a complete risk-benefit assessment. The potential for cardiovascular benefits associated with weight loss must be carefully weighed against the potential for increased cardiovascular risk in specific patient groups.
Timeline of Events & Key Developments
- August 2023: Results of the SELECT trial are presented, revealing potential cardiovascular risks.
- Ongoing: Regulatory agencies (FDA, EMA) are reviewing the data and assessing potential labeling changes.
- Future: Further research is planned to investigate the mechanisms behind the observed cardiovascular effects
More on this
- Higher Eosinophilic Esophagitis Prevalence Found in Pediatric Asthma Patients
- Improving Metabolism May Halve Risk of Advanced Intestinal Polyp Recurrence
- Why Do Hurricanes Stall Over Land? The Science, Explained (daybreakwire.com)
- German Government Law Aims to Stop Rising Health Insurance Contributions (archyde.com)